Bone Marrow Flow Cytometry in Staging of Patients With B-cell Non-Hodgkin Lymphoma

Kim, Borahm; Lee, Seung Tae; Kim, Hee Jin; Kim, Sun Hee

doi:10.3343/alm.2015.35.2.187

Cited by 21 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Morphological assessment of bone marrow biopsy specimens is the standard method for analyzing BM lesions in NHL. Flow cytometry is an additional approach for evaluating BM in NHL, especially when detecting a small number of lymphoma cells [44]. However, this method also has limited sensitivity.…”

Section: Discussionmentioning

confidence: 99%

The Profile of MicroRNA Expression in Bone Marrow in Non-Hodgkin’s Lymphomas

et al. 2022

View full text Add to dashboard Cite

Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of malignant lymphomas that can occur in both lymph nodes and extranodal sites. Bone marrow (BM) is the most common site of extranodal involvement in NHL. The objective of this study is to determine the unique profile of miRNA expression in BM affected by NHL, with the possibility of a differential diagnosis of NHL from reactive BM changes and acute leukemia (AL). A total of 180 cytological samples were obtained by sternal puncture and aspiration biopsy of BM from the posterior iliac spine. All the cases were patients before treatment initiation. The study groups were NHL cases (n = 59) and AL cases (acute lymphoblastic leukemia (n = 25) and acute myeloid leukemia (n = 49)); the control group consisted of patients with non-cancerous blood diseases (NCBDs) (n = 48). We demonstrated that expression levels of miRNA-124, miRNA-221, and miRNA-15a are statistically significantly downregulated, while the expression level of let-7a is statistically significantly upregulated more than 2-fold in BM in NHL compared to those in AL and NCBD. ROC analysis revealed that let-7a/miRNA-124 is a highly sensitive and specific biomarker for a differential diagnosis of BM changes in NHL from those in AL and NCBD. Therefore, we conclude that analysis of miRNA expression levels may be a promising tool for early diagnosis of NHL.

show abstract

Section: Discussionmentioning

confidence: 99%

The Profile of MicroRNA Expression in Bone Marrow in Non-Hodgkin’s Lymphomas

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Flow cytometry has been applied to analyze bone marrow aspirates for routine staging of non-Hodgkin lymphoma (NHL) patients or immunophenotyping of leukemia [ 27 , 28 ]. Therefore, in this study, we leveraged the same flow cytometry technology platform to detect dengue viral antigen.…”

Section: Discussionmentioning

confidence: 99%

Establishment and Comparison of Two Different Diagnostic Platforms for Detection of DENV1 NS1 Protein

Tang

Chiu

Lin

et al. 2015

IJMS

View full text Add to dashboard Cite

Dengue virus (DENV) infection is currently at pandemic levels, with populations in tropical and subtropical regions at greatest risk of infection. Early diagnosis and management remain the cornerstone for good clinical outcomes, thus efficient and accurate diagnostic technology in the early stage of the disease is urgently needed. Serotype-specific monoclonal antibodies (mAbs) against the DENV1 nonstructural protein 1 (NS1), DA12-4, DA13-2, and DA15-3, which were recently generated using the hybridoma technique, are suitable for use in diagnostic platforms. Immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA) and Western blot analysis further confirmed the serotype specificity of these three monoclonal antibodies. The ELISA-based diagnostic platform was established using the combination of two highly sensitive mAbs (DA15-3 and DB20-6). The same combination was also used for the flow cytometry-based diagnostic platform. We report here the detection limits of flow cytometry-based and ELISA-based diagnostic platforms using these mAbs to be 0.1 and 1 ng/mL, respectively. The collected clinical patient serum samples were also assayed by these two serotyping diagnostic platforms. The sensitivity and specificity for detecting NS1 protein of DENV1 are 90% and 96%, respectively. The accuracy of our platform for testing clinical samples is more advanced than that of the two commercial NS1 diagnostic platforms. In conclusion, our platforms are suitable for the early detection of NS1 protein in DENV1 infected patients.

show abstract

“…Increase of CD3 + CD7 − T cells in bone marrow predicts invasion in patients with T-cell non-Hodgkin's lymphoma emission tomography-computed tomography (PET-CT) (6,7), T-cell receptor (TCR) gene rearrangement (3,8), flow cytometry (9)(10)(11) have been greatly improved, and gradually become required examinations when the BM invasion of T-NHL was assessed. Although a growing body of evidence manifests that BM biopsy is still an irreplaceable diagnostic method (11) and the current pathological diagnosis has certain limitations, a pathological evaluation is one of the most important methods for the diagnosis of malignant lymphoma with BM invasion (12). The method based on flow cytometry has a high sensitivity, making it easier to detect the minimal BM invasion (9).…”

Section: Original Articlementioning

confidence: 99%

“…So far, BM biopsy and BM pathology are still the gold standard for diagnosis of BM invasion in T-NHL ( 5 ). However, with the technology development, several methods such as positron emission tomography-computed tomography (PET-CT) ( 6 , 7 ), T-cell receptor (TCR) gene rearrangement ( 3 , 8 ), flow cytometry ( 9 - 11 ) have been greatly improved, and gradually become required examinations when the BM invasion of T-NHL was assessed. Although a growing body of evidence manifests that BM biopsy is still an irreplaceable diagnostic method ( 11 ) and the current pathological diagnosis has certain limitations, a pathological evaluation is one of the most important methods for the diagnosis of malignant lymphoma with BM invasion ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

Increase of CD3+CD7− T cells in bone marrow predicts invasion in patients with T-cell non-Hodgkin’s lymphoma

Huang¹,

Chen²,

Ling³

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background The T-cell non-Hodgkin’s lymphoma (T-NHL) patients with bone marrow (BM) invasion have a poor prognosis. Although BM biopsy is still a confirmed diagnosis method, the low sensitivity restricts its use to detect the minimal BM invasion. It is of great clinical significance to establish a rapid and highly sensitive method to evaluate BM invasion. Methods We conducted a retrospective study of 85 patients with new diagnosed T-NHL patients enrolled in our institute. The bone marrow mononuclear cells (BMMNCs) cells were isolated, stained with different combinations of antibody and subjected to flow cytometry analysis. Results We found that CD3 + CD7 − T cells increased significantly in the BM in T-NHL patients with BM invasion. The patients were divided into the low and high groups according to the cutoff value of 1.035% obtained by analyzing the receiver operating characteristic (ROC) curve of the percentage of CD3 + CD7 − T cells of nucleated cells at diagnosis. The ratio of invasion in high group was markedly higher than that in low group. Furthermore, CD3 + CD7 − T cells presented significantly higher level of programmed cell death-1 (PD-1), lymphocyte-activation-gene-3 (LAG3) and CD4/CD8 ratio. Conclusions Our study revealed the percentage of CD3 + CD7 − T cells of nucleated cells in BM was a potential diagnostic predictor of BM invasion with T-NHL.

show abstract

Bone Marrow Flow Cytometry in Staging of Patients With B-cell Non-Hodgkin Lymphoma

Cited by 21 publications

References 26 publications

The Profile of MicroRNA Expression in Bone Marrow in Non-Hodgkin’s Lymphomas

The Profile of MicroRNA Expression in Bone Marrow in Non-Hodgkin’s Lymphomas

Establishment and Comparison of Two Different Diagnostic Platforms for Detection of DENV1 NS1 Protein

Increase of CD3+CD7− T cells in bone marrow predicts invasion in patients with T-cell non-Hodgkin’s lymphoma

Contact Info

Product

Resources

About